HIV/Hepatitis C Virus−Coinfected Virologic Responders to Pegylated Interferon and Ribavirin Therapy More Frequently Incur Interferon-Related Adverse Events Than Nonresponders Do
Authors:
- Joseph J RasimasJRJoseph J Rasimas
- Rachel BishopRBRachel Bishop
- Michael ProschanMPMichael Proschan
- Mary RN McLaughlinMMMary RN McLaughlin
- Alison Ba MurphyAMAlison Ba Murphy
- Karoll J CortezKCKaroll J Cortez
- Michael A PolisMPMichael A Polis
- Henry MasurHMHenry Masur
- Donald RosensteinDRDonald Rosenstein
- Shyam KottililSKShyam Kottilil
- 1 March 2010
- journal article
- clinical trial
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 53 (3) , 357-363
Abstract
Background: This study aimed to assess the relationship between interferon (IFN)-related adverse effects and Hepatitis C virus (HCV) virologic response in HIV/HCV-coinfected individuals treated with pegylated interferon and ribavirin. Methods: We conducted 2 prospective, open-label trials treating HIV/HCV-coinfected individuals with pegylated interferon alpha-2b or alpha-2a and ribavirin for 48 weeks. Safety laboratories, HCV RNA, psychiatric, and ophthalmologic evaluations were performed at baseline and monthly until week 72. Results: Responders were defined as those with HCV RNA decline of ≥2-log drop from baseline and nonresponders were those who did not. Remarkably, of the 27 patients (50%) who developed psychiatric toxicities, 26 patients were responders, although only 1 of 14 virologic nonresponders experienced psychiatric toxicity. Other adverse effects, such as anemia and ophthalmologic toxicities, were also more frequent in responders compared with nonresponders. Decline in CD4+ T-cell counts strongly correlated with HCV viral decline. Conclusions: Our study demonstrates coupling of antiviral effect and occurrence of adverse events in HIV/HCV-coinfected patients. These patients with IFN-related adverse effects need a multidisciplinary treatment approach, hence, they are more likely to achieve sustained virologic response. Future studies are needed to evaluate the factors that predict the development of IFN-α-dependent adverse events before therapy.Keywords
This publication has 33 references indexed in Scilit:
- Predictors for Hematopoietic Growth Factors Use in HIV/HCV-Coinfected Patients Treated with Peginterferon Alfa 2b and RibavirinAIDS Patient Care and STDs, 2006
- Pegylated interferon α-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patientsJournal of Infection, 2006
- Gene Expression Profiles in Hepatitis C Virus (HCV) and HIV Coinfection: Class Prediction Analyses before Treatment Predict the Outcome of Anti‐HCV Therapy among HIV‐Coinfected PersonsThe Journal of Infectious Diseases, 2006
- Treatment of viral hepatitis in HIV–coinfected patients–adverse events and their managementJournal of Hepatology, 2005
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancerAnnals of Oncology, 2005
- HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management ForumThe Oncologist, 2005
- Association of interferon-α-induced depression and improved treatment response in patients with hepatitis CNeuroscience Letters, 2004
- Hematologic Disorders Associated with Hepatitis C Virus Infection and Their ManagementClinical Infectious Diseases, 2003
- Neurobehavioral Effects of Interferon-α in Cancer Patients Phenomenology and Paroxetine Responsiveness of Symptom DimensionsNeuropsychopharmacology, 2002